Shares of Dabur India will remain in focus on Friday after the FMCG major said that the US FDA has issued an import alert for drugs manufactured by the company at its manufacturing plant situated in Silvassa in Dadra and Nagar Haveli.
The FDA inspected Dabur’s plant and identified certain deficiencies on account of data integrity and maintenance lapses. After the conclusion of the inspection, Dabur received inspectional observations, to which it has submitted its responses.
